Seattle Genetics (SGEN) Announces ADCETRIS Receives EC Approval for CD30-Positive Cutaneous T-Cell Lymphoma after at Least One Prior Systemic Therapy
Tweet Send to a Friend
Seattle Genetics, Inc. (Nasdaq: SGEN) reported today that its collaborator, Takeda Pharmaceutical Company Limited, announced that the European Commission has ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
